Epidemiology and Comorbidities of Polycystic Ovary Syndrome in an Indigent Population

被引:58
|
作者
Sirmans, Susan M. [1 ]
Parish, Roy C. [1 ,2 ]
Blake, Sandra [3 ]
Wang, Xiaojun [3 ]
机构
[1] Univ Louisiana Monroe, Sch Pharm, Baton Rouge, LA 70806 USA
[2] Louisiana State Univ, Sch Med, Dept Internal Med, Hlth Sci Ctr, Shreveport, LA USA
[3] Univ Louisiana Monroe, Coll Pharm, Off Outcomes Res, Baton Rouge, LA 70806 USA
关键词
polycystic ovary syndrome; cardiovascular risk factors; anxiety; bipolar disorders; depression; eating disorders; infertility; obstructive sleep apnea; IMPAIRED GLUCOSE-TOLERANCE; OBSTRUCTIVE SLEEP-APNEA; INCREASED PREVALENCE; BIPOLAR DISORDER; COMMUNITY SAMPLE; INCREASED RISK; OBESE WOMEN; CORONARY; HEALTH; ATHEROSCLEROSIS;
D O I
10.1097/01.JIM.0000446834.90599.5d
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. The aims of this study were to provide an estimate of the prevalence of PCOS in clinical practice; compare the risk of established cardiovascular risk factors, cardiovascular disease, and other comorbid conditions in women with PCOS to that of age-and race-matched controls; and explore the total costs of care that can be attributed to PCOS. Methods: Louisiana Medicaid claims data were used to identify women with PCOS or its defining features and a control group in a ratio of 1: 3. The prevalence of PCOS, cardiovascular risk factors (diabetes, dyslipidemia, dysmetabolic syndrome, glucose intolerance, hypertension, and obesity), key comorbidities (anxiety, bipolar disorders, depression, eating disorders, infertility, obstructive sleep apnea), and diagnosed cardiovascular disease were measured. Results: During 2010, the prevalence of PCOS was 0.88%. Women with PCOS were more likely to have a diagnosis of diabetes (odds ratio [OR], 4.35; 95% confidence interval [CI], 3.63-5.21), dyslipidemia (OR, 3.56; 95% CI, 3.04-4.19), dysmetabolic syndrome (OR, 23.46; 95% CI, 13.64-40.36), glucose intolerance (OR, 5.46; 95% CI, 3.10-9.60), hypertension (OR, 2.76; 95% CI, 2.41-3.18), obesity (OR, 5.79; 95% CI, 5.07-6.62), infertility (OR, 23.42; 95% CI, 10.63-51.61), obstructive sleep apnea (OR, 6.47; 95% CI, 3.62-11.55), anxiety (OR, 1.76; 95% CI, 1.53-2.04), bipolar disorders (OR, 1.94; 95% CI, 1.55-2.44), and depression (OR, 2.22; 95% CI, 1.94-2.54) than did controls. Average total costs of care for the year was $5551 in the PCOS group and $3496 in the control group. After controlling for the effects of other variables, the average total cost of care for PCOS was $637 higher than that of the control group. Other variables that contributed significantly to the total costs of care included race, age, acute myocardial infarction, transient ischemic attack, peripheral artery disease, anxiety, depression, bipolar disorders, hypertension, diabetes, and dyslipidemia. Conclusions: Although the clinical burden of PCOS is high, it is diagnosed less frequently in clinical practice compared with systematic screening studies. This is concerning considering that PCOS is associated with cardiovascular risk factors and other comorbidities. Mean total costs of care for the PCOS group was higher than the mean total costs of care for the control group. Polycystic ovary syndrome is independently associated with an increase in mean total costs of care.
引用
收藏
页码:868 / 874
页数:7
相关论文
共 50 条
  • [21] The prevalence and features of the polycystic ovary syndrome in an unselected population
    Azziz, R
    Woods, KS
    Reyna, R
    Key, TJ
    Knochenhauer, ES
    Yildiz, BO
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06): : 2745 - 2749
  • [22] Polycystic ovary syndrome and arrhythmic risk: the role of comorbidities and the prevalence of interatrial block
    Russo, Vincenzo
    Nigro, Gerardo
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2016, 16 (09): : 730 - 730
  • [23] Primary and secondary prevention of metabolic and cardiovascular comorbidities in women with polycystic ovary syndrome
    Spritzer, Poli Mara
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2015, 37 (01): : 1 - 4
  • [24] Perspectives on Polycystic Ovary Syndrome: Is Polycystic Ovary Syndrome Research Underfunded?
    Brakta, Soumia
    Lizneva, Daria
    Mykhalchenko, Kateryna
    Imam, Adonis
    Walker, Walidah
    Diamond, Michael P.
    Azziz, Ricardo
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (12): : 4421 - 4427
  • [25] Ethnic-specific polycystic ovary syndrome: epidemiology, significance and implications
    Wijeyaratne, Chandrika N.
    Udayangani, S. A. Dilini
    Balen, Adam H.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (01) : 71 - 79
  • [26] Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome
    Lo, JC
    Feigenbaum, SL
    Yang, JR
    Pressman, AR
    Selby, JV
    Go, AS
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (04): : 1357 - 1363
  • [27] The epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome: The Kaiser Permanente polycystic ovary syndrome (KP-PCOS) study
    Lo, Joan C.
    Feigenbaum, Seth L.
    Yang, Jingrong
    Pressman, Alice R.
    Selby, Joe V.
    Go, Alan S.
    JOURNAL OF WOMENS HEALTH, 2006, 15 (06) : 679 - 679
  • [28] Polycystic ovary syndrome
    King, Joyce
    JOURNAL OF MIDWIFERY & WOMENS HEALTH, 2006, 51 (06) : 415 - 422
  • [29] Polycystic ovary syndrome
    不详
    MEDICINA DELLO SPORT, 2007, 60 (03) : 440 - 444
  • [30] Polycystic ovary syndrome
    Guzick, DS
    OBSTETRICS AND GYNECOLOGY, 2004, 103 (01): : 181 - 193